PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

著者: Frederick J. Raal, Evan A. Stein, Robert Dufour, Traci Turner, Fernando Civeira, Lesley Burgess, Gisle Langslet, Russell Scott, Anders Olsson, David Sullivan, G. Kees Hovingh, Bertrand Cariou, Ioanna Gouni‐Berthold, Ransi Somaratne, Ian Bridges, Robert C. Scott, Scott M. Wasserman, Daniel Gaudet - The Lancet 2014 被引用: 751